Literature DB >> 18923873

Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines.

Craig L Slingluff1, Galina V Yamshchikov, Kevin T Hogan, Sarah C Hibbitts, Gina R Petroni, Eric A Bissonette, James W Patterson, Patrice Y Neese, William W Grosh, Kimberly A Chianese-Bullock, Andrea Czarkowski, Patrice K Rehm, Jayashree Parekh.   

Abstract

BACKGROUND: We hypothesized that lymph nodes draining sites of cutaneous vaccination could be identified by sentinel node biopsy techniques, and that measuring T-cell response with lymphocytes obtained from these lymph nodes would provide a more sensitive measure of immunogenicity than would the same measurement made with peripheral blood lymphocytes (PBL).
METHODS: ELISpot analysis was used to determine the magnitude of vaccine-specific T-cell response in the sentinel immunized nodes (SIN), random lymph nodes, and peripheral blood lymphocytes (PBL) obtained from patients enrolled in clinical trials of experimental melanoma vaccines.
RESULTS: The SIN biopsy was successful in 97% of cases and morbidity was very low. The T-cell response to vaccination was detected with greater sensitivity in the SIN (57%) than in PBL (39%), and evaluation of T-cell responses in the SIN and the PBL together yielded T-cell responses in 63% of patients. When the T-cell responses from a SIN and a random lymph node were compared in four patients, immune responses were detected to one of the vaccine peptides in three of these four patients. In all of those cases, responses were present in the SIN but absent from the random lymph node.
CONCLUSION: Measurements of T-cell responsiveness to cutaneous immunization are more frequently positive in the SIN than they are in the PBL, however evaluation of both the SIN and PBL permit a more sensitive measure of T-cell immunogenicity than use of either single source.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18923873      PMCID: PMC2997393          DOI: 10.1245/s10434-008-0046-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  37 in total

1.  Localization of HLA-A2.1-restricted T cell epitopes in the circumsporozoite protein of Plasmodium falciparum.

Authors:  U Blum-Tirouvanziam; C Servis; A Habluetzel; D Valmori; Y Men; F Esposito; L Del Nero; N Holmes; N Fasel; G Corradin
Journal:  J Immunol       Date:  1995-04-15       Impact factor: 5.422

2.  Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.

Authors:  M R Parkhurst; M L Salgaller; S Southwood; P F Robbins; A Sette; S A Rosenberg; Y Kawakami
Journal:  J Immunol       Date:  1996-09-15       Impact factor: 5.422

3.  Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.

Authors:  J C Skipper; D J Kittlesen; R C Hendrickson; D D Deacon; N L Harthun; S N Wagner; D F Hunt; V H Engelhard; C L Slingluff
Journal:  J Immunol       Date:  1996-12-01       Impact factor: 5.422

4.  An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins.

Authors:  J C Skipper; R C Hendrickson; P H Gulden; V Brichard; A Van Pel; Y Chen; J Shabanowitz; T Wolfel; C L Slingluff; T Boon; D F Hunt; V H Engelhard
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

5.  Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.

Authors:  Craig L Slingluff; Gina R Petroni; Kimberly A Chianese-Bullock; Mark E Smolkin; Sarah Hibbitts; Cheryl Murphy; Naomi Johansen; William W Grosh; Galina V Yamshchikov; Patrice Y Neese; James W Patterson; Robyn Fink; Patrice K Rehm
Journal:  Clin Cancer Res       Date:  2007-11-01       Impact factor: 12.531

6.  Intracellular transport of class I MHC molecules in antigen processing mutant cell lines.

Authors:  K S Anderson; J Alexander; M Wei; P Cresswell
Journal:  J Immunol       Date:  1993-10-01       Impact factor: 5.422

7.  Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

Authors:  A L Cox; J Skipper; Y Chen; R A Henderson; T L Darrow; J Shabanowitz; V H Engelhard; D F Hunt; C L Slingluff
Journal:  Science       Date:  1994-04-29       Impact factor: 47.728

8.  Peptide-induced modulation of target cell sensitivity to natural killing.

Authors:  W J Storkus; R D Salter; P Cresswell; J R Dawson
Journal:  J Immunol       Date:  1992-08-15       Impact factor: 5.422

9.  Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area.

Authors:  A Rosato; A Zambon; B Macino; S Mandruzzato; V Bronte; G Milan; P Zanovello; D Collavo
Journal:  Int J Cancer       Date:  1996-03-15       Impact factor: 7.396

10.  Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes.

Authors:  B Gaugler; B Van den Eynde; P van der Bruggen; P Romero; J J Gaforio; E De Plaen; B Lethé; F Brasseur; T Boon
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

View more
  14 in total

1.  Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma.

Authors:  Caroline J Voskens; Duane Sewell; Ronna Hertzano; Jennifer DeSanto; Sandra Rollins; Myounghee Lee; Rodney Taylor; Jeffrey Wolf; Mohan Suntharalingam; Brian Gastman; John C Papadimitriou; Changwan Lu; Ming Tan; Robert Morales; Kevin Cullen; Esteban Celis; Dean Mann; Scott E Strome
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

2.  A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602).

Authors:  Craig L Slingluff; Sandra Lee; Fengmin Zhao; Kimberly A Chianese-Bullock; Walter C Olson; Lisa H Butterfield; Theresa L Whiteside; Philip D Leming; John M Kirkwood
Journal:  Clin Cancer Res       Date:  2013-05-07       Impact factor: 12.531

3.  Paradoxical decrease in the capture and lymph node delivery of cancer vaccine antigen induced by a TLR4 agonist as visualized by dual-mode imaging.

Authors:  Deepak K Kadayakkara; Michael J Korrer; Jeff W M Bulte; Hyam I Levitsky
Journal:  Cancer Res       Date:  2014-11-11       Impact factor: 12.701

4.  Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines.

Authors:  Craig L Slingluff; Gina R Petroni; Mark E Smolkin; Kimberly A Chianese-Bullock; Kelly Smith; Cheryl Murphy; Nadedja Galeassi; Patrice Y Neese; William W Grosh; Carmel J Nail; Merrick Ross; Margaret von Mehren; Naomi Haas; Marc E Boisvert; John M Kirkwood
Journal:  J Immunother       Date:  2010 Jul-Aug       Impact factor: 4.456

5.  A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.

Authors:  Craig L Slingluff; Gina R Petroni; Walter C Olson; Mark E Smolkin; Kimberly A Chianese-Bullock; Ileana S Mauldin; Kelly T Smith; Donna H Deacon; Nikole E Varhegyi; Sean B Donnelly; Caroline M Reed; Kristy Scott; Nadejda V Galeassi; William W Grosh
Journal:  Cancer Immunol Immunother       Date:  2015-11-18       Impact factor: 6.968

6.  Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis.

Authors:  Jochen T Schaefer; James W Patterson; Donna H Deacon; Mark E Smolkin; Gina R Petroni; Emily M Jackson; Craig L Slingluff
Journal:  J Transl Med       Date:  2010-08-20       Impact factor: 5.531

7.  A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes.

Authors:  Patrick M Dillon; Walter C Olson; Andrea Czarkowski; Gina R Petroni; Mark Smolkin; William W Grosh; Kimberly A Chianese-Bullock; Donna H Deacon; Craig L Slingluff
Journal:  J Immunother Cancer       Date:  2014-07-15       Impact factor: 13.751

8.  A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.

Authors:  Marit M Melssen; Gina R Petroni; Kimberly A Chianese-Bullock; Nolan A Wages; William W Grosh; Nikole Varhegyi; Mark E Smolkin; Kelly T Smith; Nadejda V Galeassi; Donna H Deacon; Elizabeth M Gaughan; Craig L Slingluff
Journal:  J Immunother Cancer       Date:  2019-06-27       Impact factor: 13.751

9.  Using magnetic resonance imaging to evaluate dendritic cell-based vaccination.

Authors:  Peter M Ferguson; Angela Slocombe; Richard D Tilley; Ian F Hermans
Journal:  PLoS One       Date:  2013-05-29       Impact factor: 3.240

10.  Vaccine-draining lymph nodes of cancer patients for generating anti-cancer antibodies.

Authors:  Girja S Shukla; Walter C Olson; Stephanie C Pero; Yu-Jing Sun; Chelsea L Carman; Craig L Slingluff; David N Krag
Journal:  J Transl Med       Date:  2017-08-29       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.